Glenmark and BeiGene entered into an agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India
• Tislelizumab is a novel anti-PD-1 monoclonal antibody approved by NMPA, EMA and FDA for the treatment of advanced or metastatic
Read More